search
Back to results

Antimicrobial Stewardship Interventions in a Hospital Setting

Primary Purpose

Infectious Disease

Status
Completed
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions
Sponsored by
Uppsala University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infectious Disease focused on measuring antimicrobial stewardship, prospective audit and feedback, infectious diseases, randomized trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Randomization to intervention arms is performed on ward level.

Eligibility criteria:

- Surgical or medical wards

Patient level (too be included in the outcome analyses)

Inclusion Criteria:

  • At least 18 years of age
  • Ongoing antimicrobial therapy on a study ward
  • Signed informed consent

Exclusion Criteria:

  • Patients in palliative care with very short life expectancy
  • Patients from another county than study site

Sites / Locations

  • Uppsala University Hospital
  • Ystads lasarett

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Infectious diseases physician led

Multiprofessional team

Arm Description

Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly Also including standard of care infectious disease consultant on demand hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)

Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention Also including standard of care infectious disease consultant on demand hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)

Outcomes

Primary Outcome Measures

Change and trends in days of antibiotic therapy (DOT)/100 patient days
Monthly DOT of antibiotics per 100 patient days on ward level assessed 5 y pre-intervention and 1 y post-intervention. Data will be analysed using interrupted time series analysis to assess immediate changes following implementation and comparison of trends before and after the intervention.

Secondary Outcome Measures

Days of defined daily doses (DDDs)/100 patient days
Overall days of therapy per 100 patient days (PD) on the ward level
Treatment duration (Days per treatment period overall)
Overall days per treatment episode. A treatment episode is defined as antimicrobial treatment not interrupted by more than one calendar day.
30-d mortality
All cause 30-d mortality
In-hospital mortality
All-cause in-hospital mortality
Hospital readmission within 30 d after discharge
Unplanned hospital readmission within 30 d after discharge
Hospital readmission due to relapse of infection within 30 d after discharge
Unplanned hospital readmission due to relapse of infection within 30 d after discharge
Hospital length of stay (LOS)
Hospital length of stay per admission
Intensive Care Unit (ICU) transfer
Proportion of admissions transferred to ICU after initial non-ICU admission
Guideline compliance
Proportion of patients treated where antimicrobial therapy was in compliance with local guideline, or in absence of local guideline national guideline
De-escalation or shift to targeted therapy
Proportion of patients where de-escalation or shift to targeted antibiotic therapy occurred within 72 hours after initiation of treatment
Intravenous to oral switch
Proportion of patients where intravenous antibiotics was shifted to oral therapy within 5 days (if appropriate)
Appropriate diagnostic examinations
Proportion of patients with appropriate diagnostic examinations performed, according to local guidelines, or in the absence of local guidelines national guidelines
Dose adjustment for renal function within 48 h after initiation of antimicrobial therapy at admission
Dose adjustment of antimicrobial after the most critical phase of the infection
Dose adjustment for renal function when initiating antimicrobial therapy in a non-acute situation
Proportion of antimicrobial prescription in non-acute situations where dosing was according to renal function
Therapeutic drug monitoring (TDM)
Proportion of patients where TDM was used, when applicable according to local guideline
Drug-drug interactions (DDI)
Important DDI taken into account when prescribing antimicrobial therapy
Incidence of Clostridium difficile infections (CDI)
Incidence of healthcare-facility onset CDI denominated by 10 000 PD and admission
Incidence of multidrug-resistant organisms (MDRO)
Incidence of clinical cultures with multidrug resistant organisms (methicillin-resistant Staphylococcus aureus (MRSA), Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E), carbapenemase-producing Enterobacteriaceae (CPE), vancomycin-resistant enterococci (VRE), multidrug resistant P. aeruginosa) denominated per 1000 PD and admissions
Costs of administered antimicrobials
Costs of administered antimicrobials (overall and by class) per admission and per patient receiving antibiotics
Costs of the intervention
Total costs of the intervention

Full Information

First Posted
June 20, 2019
Last Updated
December 1, 2022
Sponsor
Uppsala University
Collaborators
Lund University
search

1. Study Identification

Unique Protocol Identification Number
NCT04001309
Brief Title
Antimicrobial Stewardship Interventions in a Hospital Setting
Official Title
A Randomized Antimicrobial Stewardship Trial in a Hospital Setting
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
July 1, 2019 (Actual)
Primary Completion Date
July 31, 2022 (Actual)
Study Completion Date
July 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Uppsala University
Collaborators
Lund University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The emerging crisis of multidrug-resistant bacteria is accelerated by a massive overuse and misuse of antibiotics. It has been estimated that 50% of antibiotic prescriptions are inappropriate. Antibiotic interventions to improve prescribing patterns have been successfully implemented in primary care in Sweden and other countries. However, much of the last-resort antibiotics are used in hospitals in which decisions on therapy for bacterial infections are more complex. In this project we will explore the appropriateness of antibiotic prescribing in a hospital setting and measures to improve the quality of antimicrobial therapy. Antimicrobial stewardship interventions will be conducted at selected hospital departments using prospective audit and feedback in a multifaceted and cross-disciplinary approach. The intervention effects on antibiotic consumption, appropriateness of prescriptions, patient outcome and emergence of resistance will be evaluated, and a financial cost-effectiveness analysis will be performed.
Detailed Description
Background: In this project we will address the issue of inappropriate antibiotic prescribing in a hospital setting using a systematic and cross-disciplinary approach. We believe that a substantial reduction in antibiotic use and a significant improvement in prescribing patterns can be achieved, which will benefit the patients by reducing the risks of side effects such as antibiotic-induced Clostridium difficile enteritis. Aim: The aim of this study is to implement and evaluate antibiotic interventions at targeted hospital wards. Method: Hospital wards will be randomised to one of two antimicrobial stewardship intervention arms stratified by specialty (medicine or surgery). Prospective audit and feedback is a core intervention strategy in both arms. Statistics: Interrupted time-series analysis (ITS) will be used for the primary endpoint; volume of antimicrobial prescribing. Monthly baseline data at least five years prior to start of the intervention and a during a follow-up period of at least 12 months after end of the intervention period will be used to assess immediate and sustained effects. Endpoints and outcomes: Primary endpoint is reduction in antibiotic use, days of antibiotic therapy (DOTs)/100 patient days Secondary endpoints include outcome measures for quantity of antibiotic use, appropriateness of prescriptions, clinical and microbiological outcome and cost-effectiveness. Data on antibiotic use and trends in prescriptions of key antibiotics will be obtained from hospital pharmacies. Data on duration of hospitalization, patient mortality, re-admissions and side effects including antibiotic-associated Clostridium difficile enteritis will be extracted from the medical records to assess potential impact on patient outcome caused by the intervention. Data on emergence of resistance during therapy and general trends in resistance epidemiology will be recorded. The outcome assessment will include a survey to participating physicians on the value different aspects of the stewardship intervention in their daily care of patients with infections. A cost-effectiveness analysis of the intervention will be performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infectious Disease
Keywords
antimicrobial stewardship, prospective audit and feedback, infectious diseases, randomized trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized clinical trial
Masking
Outcomes Assessor
Masking Description
Masking for care providers and investigators is not feasible. Outcomes assessors will be blinded to study period and intervention arms when evaluating appropriateness of prescribing.
Allocation
Randomized
Enrollment
1312 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Infectious diseases physician led
Arm Type
Experimental
Arm Description
Prospective audit and feedback of antimicrobial therapy by infectious disease physicians twice weekly Also including standard of care infectious disease consultant on demand hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)
Arm Title
Multiprofessional team
Arm Type
Experimental
Arm Description
Prospective audit and feedback of antimicrobial therapy by infectious disease physicians once weekly, ward clinical pharmacists thrice weekly and engagement of ward nurses in the stewardship intervention Also including standard of care infectious disease consultant on demand hospital antimicrobial stewardship program as usual (education, general information, feedback on prescribing)
Intervention Type
Other
Intervention Name(s)
Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions
Intervention Description
Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
Primary Outcome Measure Information:
Title
Change and trends in days of antibiotic therapy (DOT)/100 patient days
Description
Monthly DOT of antibiotics per 100 patient days on ward level assessed 5 y pre-intervention and 1 y post-intervention. Data will be analysed using interrupted time series analysis to assess immediate changes following implementation and comparison of trends before and after the intervention.
Time Frame
7 years
Secondary Outcome Measure Information:
Title
Days of defined daily doses (DDDs)/100 patient days
Description
Overall days of therapy per 100 patient days (PD) on the ward level
Time Frame
12 months
Title
Treatment duration (Days per treatment period overall)
Description
Overall days per treatment episode. A treatment episode is defined as antimicrobial treatment not interrupted by more than one calendar day.
Time Frame
12 months
Title
30-d mortality
Description
All cause 30-d mortality
Time Frame
12 months
Title
In-hospital mortality
Description
All-cause in-hospital mortality
Time Frame
12 months
Title
Hospital readmission within 30 d after discharge
Description
Unplanned hospital readmission within 30 d after discharge
Time Frame
12 months
Title
Hospital readmission due to relapse of infection within 30 d after discharge
Description
Unplanned hospital readmission due to relapse of infection within 30 d after discharge
Time Frame
12 months
Title
Hospital length of stay (LOS)
Description
Hospital length of stay per admission
Time Frame
12 months
Title
Intensive Care Unit (ICU) transfer
Description
Proportion of admissions transferred to ICU after initial non-ICU admission
Time Frame
12 months
Title
Guideline compliance
Description
Proportion of patients treated where antimicrobial therapy was in compliance with local guideline, or in absence of local guideline national guideline
Time Frame
12 months
Title
De-escalation or shift to targeted therapy
Description
Proportion of patients where de-escalation or shift to targeted antibiotic therapy occurred within 72 hours after initiation of treatment
Time Frame
12 months
Title
Intravenous to oral switch
Description
Proportion of patients where intravenous antibiotics was shifted to oral therapy within 5 days (if appropriate)
Time Frame
12 months
Title
Appropriate diagnostic examinations
Description
Proportion of patients with appropriate diagnostic examinations performed, according to local guidelines, or in the absence of local guidelines national guidelines
Time Frame
12 months
Title
Dose adjustment for renal function within 48 h after initiation of antimicrobial therapy at admission
Description
Dose adjustment of antimicrobial after the most critical phase of the infection
Time Frame
12 months
Title
Dose adjustment for renal function when initiating antimicrobial therapy in a non-acute situation
Description
Proportion of antimicrobial prescription in non-acute situations where dosing was according to renal function
Time Frame
12 months
Title
Therapeutic drug monitoring (TDM)
Description
Proportion of patients where TDM was used, when applicable according to local guideline
Time Frame
12 months
Title
Drug-drug interactions (DDI)
Description
Important DDI taken into account when prescribing antimicrobial therapy
Time Frame
12 months
Title
Incidence of Clostridium difficile infections (CDI)
Description
Incidence of healthcare-facility onset CDI denominated by 10 000 PD and admission
Time Frame
12 months
Title
Incidence of multidrug-resistant organisms (MDRO)
Description
Incidence of clinical cultures with multidrug resistant organisms (methicillin-resistant Staphylococcus aureus (MRSA), Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E), carbapenemase-producing Enterobacteriaceae (CPE), vancomycin-resistant enterococci (VRE), multidrug resistant P. aeruginosa) denominated per 1000 PD and admissions
Time Frame
12 months
Title
Costs of administered antimicrobials
Description
Costs of administered antimicrobials (overall and by class) per admission and per patient receiving antibiotics
Time Frame
12 months
Title
Costs of the intervention
Description
Total costs of the intervention
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Randomization to intervention arms is performed on ward level. Eligibility criteria: - Surgical or medical wards Patient level (too be included in the outcome analyses) Inclusion Criteria: At least 18 years of age Ongoing antimicrobial therapy on a study ward Signed informed consent Exclusion Criteria: Patients in palliative care with very short life expectancy Patients from another county than study site
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Tängdén, MD, Phd
Organizational Affiliation
Uppsala University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Uppsala University Hospital
City
Uppsala
Country
Sweden
Facility Name
Ystads lasarett
City
Ystad
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Antimicrobial Stewardship Interventions in a Hospital Setting

We'll reach out to this number within 24 hrs